Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | PLA2G2A | P14555 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL13026138 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13046610 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL5072889 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL3392690 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL24556970 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12738245 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21790369 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 1.00 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123175-A1 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells | HILL G CRAIG (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123175-A1 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells | HILL G CRAIG (US) | 2013-05-16 | — | — | US | disclosed |
| US-8232251-B2 | Compounds for delivery of therapeutic and imaging moieties to nerve cells | MANZANITA PHARMACEUTICALS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232251-B2 | Compounds for delivery of therapeutic and imaging moieties to nerve cells | MANZANITA PHARMACEUTICALS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090286732-A1 | COMPOUNDS FOR DELIVERY OF THERAPEUTIC AND IMAGING MOIETIES TO NERVE CELLS | MANZANITA PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286732-A1 | COMPOUNDS FOR DELIVERY OF THERAPEUTIC AND IMAGING MOIETIES TO NERVE CELLS | MANZANITA PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286732-A1 | COMPOUNDS FOR DELIVERY OF THERAPEUTIC AND IMAGING MOIETIES TO NERVE CELLS | CLTB, NMBR, L1CAM | NR3C1 3019/4885HIF1A 2375/4885CYP3A4 3933/4885 |
| US-20130123175-A1 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells | CLTB, NMBR, L1CAM | NR3C1 3019/4885HIF1A 2375/4885CYP3A4 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.